---
title: 'Head of IR at Attovia Therapeutics'
canonical: 'https://feeny.ai/job/head-of-ir-attovia-therapeutics-san-carlos-gzaqh4z58m0y'
type: 'job'
last_seen: '2026-09-11'
---

# Head of IR at Attovia Therapeutics

- **Company:** Attovia Therapeutics
- **Location:** San Carlos, CA
- **Compensation:** $265k–$315k
- **Employment:** full-time
- **Work type:** onsite
- **Posted:** 2026-08-23
- **Last confirmed live:** 2026-09-11
- **Apply:** https://jobs.lever.co/attovia-therapeutics/f5577a2c-37b9-4b74-9551-7592bd60f910

## Job description

Attovia Therapeutics, Inc., is seeking a Head of Investor Relations to lead our investor relations function. Reporting to the CFO, the Head of Investor Relations will play a pivotal role in shaping and executing the company's investor relations strategy. This individual will help build and articulate the company's equity narrative to the global investment community — translating complex scientific, clinical, and business information into clear, compelling communications that build trust and credibility with investors and analysts.

## Key Responsibilities

- Develop and execute a comprehensive investor relations strategy aligned with the company's corporate objectives, pipeline milestones, and long-term growth ambitions
- Manage the company’s current investor relations agency and future public relations/media agency
- Serve as a day-to-day point of contact for the buy-side and sell-side investment community, fielding inquiries and building relationships with current and prospective shareholders
- Partner with agencies to manage the production of investor-facing materials, including all press releases, earnings call scripts and Q&A prep, investor presentations, media communications, fact sheets, and the annual report
- Partner with executive team to prepare for and manage quarterly earnings calls, board meetings, investor conferences, medical conferences, non-deal roadshows and R&D-day presentations
- Lead proactive and targeted investor outreach, including identifying and cultivating relationships with new institutional investors
- Monitor and analyze sell-side analyst research, market activity, shareholder composition, and peer/competitor developments; deliver regular updates and insights to executive team and the Board
- Collaborate cross-functionally with R&D, clinical development, regulatory, legal, and corporate communications to ensure accurate, consistent, and compliant messaging across all investor touchpoints
- Support corporate development activities, including materials related to M&A, partnerships, licensing deals, and capital markets transactions (e.g., follow-on offerings)
- Manage corporate website including investor relations section
- Ensure compliance with SEC regulations, Regulation FD, and other disclosure requirements in coordination with Legal
- Help build out and scale the IR function's tools, processes, and infrastructure as the company grows

## Basic Qualifications

- Bachelor's degree required; MBA, CFA, or advanced scientific degree a plus 8+ years of relevant experience in investor relations, equity research, investment banking, or corporate finance, with a meaningful portion of that experience in biotech, pharma, or life sciences
- Experience at a publicly traded biotech/pharmaceutical company strongly preferred; direct experience supporting earnings calls, roadshows, and SEC reporting cycles
- Strong understanding of financial reporting, valuation methodologies, and capital markets used by investment professionals
- Exceptional written and verbal communication skills, highly organized with meticulous attention to detail and accuracy
- Strategic thinker who can manage multiple priorities in a fast-paced, dynamic environment and deliver polished output under tight deadlines

## Preferred Qualifications

- Scientific fluency — comfort engaging with clinical and regulatory content, with the ability to translate complex science into an accessible investment narrative, especially in autoimmune diseases
- Experience with IR-specific tools (e.g., shareholder ID/CRM platforms, earnings call/webcast providers) a plus
- Proven track record building relationships and influencing across all levels of an organization, including senior executives and the Board

Attovia™ is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need.  Our product candidates are internally discovered using our proprietary ATTOBODY™ platform, an evolution-driven, high-throughput biologics platform that enables the rapid discovery and creation of diverse biparatopic complex biologics.  Our pipeline spans chronic pruritic diseases, inflammatory skin diseases, inflammatory bowel disease, and other immune-mediated conditions.

Our values define how we make decisions, work with one another, and pursue our mission:

- Integrity: We put patients first, uphold the highest ethical standards, and communicate with honesty and transparency
- Learning & Growth: We ask questions, challenge the status quo, seek and provide constructive feedback, and invest in the development of ourselves and others
- Drive for Excellence: We set ambitious goals, take ownership, honor our commitments, move with urgency, and deliver rigorous, high-quality, and data-driven work
- Innovation: We pursue transformative science, think creatively, and do more with less through resourcefulness and continuous improvement
- Teamwork & Collaboration: We communicate openly, debate constructively, mentor and learn from one another, and recognize that our strongest results come from working together

We take pride in fostering a strong team and dynamic work environment, and we are seeking individuals who align with our values and contribute to a positive and impactful workplace.

Attovia is located in San Carlos, CA.

Attovia is an equal opportunity employer. We consider all qualified applicants for employment without regard to race, color, ancestry, national origin, religion or creed, age, sex, pregnancy, childbirth, breastfeeding or related medical conditions, sexual orientation, gender, gender identity or gender expression, marital status, medical condition, genetic information, physical or mental disability, military or veteran status, reproductive health decision-making, or any other characteristic protected by applicable federal, state, or local law.

Learn more about Attovia: [www.attovia.com](https://www.attovia.com)

Notice to Employment Agencies The Attovia talent acquisition program is managed through internal resources, and unsolicited referrals and resumes are not accepted from employment agencies, unless advance written authorization is granted from the Human Resources department. Attovia shall not be liable for any fees arising from any unsolicited or unauthorized candidate information received relative to position vacancies.

## About Attovia Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases using its proprietary ATTOBODY biparatopic biologics platform.
- **Entity Type**: Private (S-1 filed for IPO)
- **Headquarters**: San Carlos, California, USA
- **Founded**: 2023
- **Founders**: Founded by a group of investors including Alamar Biosciences, Inc. (individual founders not publicly named)

## Core Business
- **Primary industry/industries**: Biopharmaceuticals, immune-mediated diseases (dermatology, gastroenterology/IBD, respiratory)
- **Target customers**: B2B (potential partnerships with larger pharma); ultimately patients with high unmet medical need
- **Mission or purpose statement**: To develop new and improved treatments for patients in need by combining scientific curiosity with impactful change, leveraging the ATTOBODY platform to design novel complex biologics.

## Products & Services
- **ATTOBODY Platform**: Proprietary evolution-driven, high-throughput discovery platform that creates biparatopic (two VHH domains) biologics with ultra-high affinity, modularity, and the ability to target two, three, or four disease-driving pathways in a single molecule. Designed for rapid candidate generation and de-risked development.
- **ATTO-1310**: Monospecific ATTOBODY targeting IL-31. Completed Phase 1 clinical trial dosing in healthy volunteers and patients (Q1 2026). Indications: chronic pruritus, atopic dermatitis, chronic pruritus of unknown origin, cholestatic pruritus, CKD-associated pruritus.
- **ATTO-2306**: Bispecific ATTOBODY targeting IL-13 and IL-31. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory skin diseases (atopic dermatitis, chronic spontaneous urticaria, prurigo nodularis).
- **ATTO-1091**: Trispecific ATTOBODY-based Fc-fusion protein targeting TL1A, IL-23p19, and integrin α4β7. In IND-enabling studies; Phase 1 expected first half of 2027. Indications: inflammatory bowel disease (ulcerative colitis, Crohn’s disease).
- **Early-stage pipeline (ATTO-006, ATTO-007, ATTO-008)**: Pre-discovery programs targeting T<sub>RM</sub> survival, immune cell survival, and multi-alarmin blockade for rheumatology, IBD, respiratory (asthma, COPD).

## Market Standing
- **Valuation/Market Cap**: Not disclosed (private; S-1 filed indicates intent to raise capital via IPO)
- **Key Metric**: Total funding not publicly disclosed; S-1 filing represents first public financial disclosure. The company is pre-revenue (clinical-stage).
- **Notable Investors/Partners**: Alamar Biosciences (in-licensor of ATTOBODY platform). Additional founding investors not named in public filings.
- **Growth Signals**: Completed Phase 1 for lead candidate ATTO-1310 within ~2 years of founding; headcount grew 35.9% year-over-year to ~40 employees; pipeline expanding into three therapeutic areas with three candidates in IND-enabling studies.

## Competitive Advantages
- **ATTOBODY platform differentiator**: Biparatopic binding enables ultra-high affinity and potency, tunable pharmacokinetics, and modular design for multispecifics (bispecifics, trispecifics, conditional “AND” gate biologics).
- **Speed of discovery**: Evolution-based high-throughput screening allows rapid nomination of multiple candidates (three within first two years).
- **Targeting clinically validated pathways**: Focus on pathways with proven commercial and clinical precedent (IL-31, IL-13, TL1A, IL-23, integrin α4β7), reducing biological risk.
- **Robust drug-like properties**: ATTOBODIES exhibit IgG-like stability and developability, potentially enabling infrequent dosing.

## Strategic Focus
- Advance ATTO-1310 through clinical development for pruritus and atopic dermatitis.
- Progress ATTO-2306 and ATTO-1091 into Phase 1 trials in 2027.
- Expand early-stage pipeline into respiratory and additional inflammatory indications.
- Leverage platform to create next-generation complex biologics that improve upon current standards of care.
- Execute IPO to fund pipeline advancement and platform expansion.

## Why Work Here
- **Culture**: Values-driven environment emphasizing integrity, continuous learning, drive for excellence, innovation, and teamwork. Described as a community of passionate scientists, inspiring leaders, and visionary executives.
- **Benefits**: Comprehensive medical/dental/vision with company premium contributions, FSA/HSA, competitive PTO and sick leave, supplemental parental leave, commute assistance, 401(k) with employer match (immediate vesting), equity grants, educational assistance, and mentorship program.
- **Work environment**: Likely on-site in San Carlos, CA (no explicit remote/hybrid policy stated). Small but rapidly growing team (~40 employees) with a flat, collaborative structure.
- **Engineering/Research culture**: High autonomy, data-driven decision-making, and focus on transformative science. Employees are encouraged to push boundaries and drive progress.

## Sources
1. [linkedin.com](https://linkedin.com/company/attovia-therapeutics) – Employee data, executives, growth
2. [attovia.com](https://www.attovia.com/careers/) – Careers page, culture, benefits
3. [attovia.com](https://www.attovia.com/pipeline/) – Pipeline overview, platform description
4. [sec.gov](https://www.sec.gov/Archives/edgar/data/2058707/000119312526303256/d40469ds1.htm) – S-1 filing, business description, financials
5. [cbinsights.com](https://www.cbinsights.com/company/attovia-therapeutics) – Profile summary, founding year, headquarters

## Other roles at Attovia Therapeutics

- [Medical Director](https://feeny.ai/job/medical-director-attovia-therapeutics-san-carlos-wvtrgawqmqne) — San Carlos, CA